Ratings Inogen, Inc.

Equities

INGN

US45780L1044

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-01 EDT			5-day change	1st Jan Change
7.05 ^USD	+3.68%		0.00%	+28.42%

02-28	Top Midday Decliners	MT
02-28	Top Premarket Decliners	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company shows low valuation levels, with an enterprise value at 0.27 times its sales.
The company appears to be poorly valued given its net asset value.
Analyst opinion has improved significantly over the past four months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
INOGEN, INC.	+28.42%	166M	B
ABBOTT LABORATORIES	-3.43%	184B	C+
MEDTRONIC PLC	-1.81%	107B	C
BECTON, DICKINSON AND COMPANY	-4.15%	67.52B	A
DEXCOM, INC.	+1.43%	50.06B	B-
CENCORA, INC.	+11.60%	45.67B	B-
HOYA CORPORATION	+3.40%	41B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+3.03%	26.73B	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.21%	26.47B	A-
TERUMO CORPORATION	+15.23%	25.05B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes